{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T15:23:44Z","timestamp":1792337024170,"version":"4.4.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.30587","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T15:46:18Z","timestamp":1634917578000},"page":"e2130587","source":"Crossref","is-referenced-by-count":43,"title":["Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment"],"prefix":"10.1001","volume":"4","author":[{"given":"Joshua D.","family":"Wallach","sequence":"first","affiliation":[{"name":"Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[{"name":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[{"name":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Community Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Health Care Policy & Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket S.","family":"Dhruva","sequence":"additional","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Health Care System, San Francisco, California"},{"name":"Department of Medicine, UCSF School of Medicine, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Flying Buttress Associates, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Berkowitz","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research and Evaluation, Yale\u2013New Haven Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Polley","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Quinto","sequence":"additional","affiliation":[{"name":"Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Springs, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Gandotra","sequence":"additional","affiliation":[{"name":"Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Springs, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Crown","sequence":"additional","affiliation":[{"name":"Florence Heller Graduate School, Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Noseworthy","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Yao","sequence":"additional","affiliation":[{"name":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Health Care Policy & Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay D.","family":"Shah","sequence":"additional","affiliation":[{"name":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Health Care Policy & Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Flying Buttress Associates, Charlottesville, Virginia"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Lyon","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"issue":"1","key":"zoi210880r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v70.1","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"zoi210880r2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.juro.2018.01.002","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline, part II: recommended approaches and details of specific care options.","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"issue":"6","key":"zoi210880r3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2017.10.002","article-title":"Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-na\u00efve prostate cancer: a systematic review and network meta-analysis.","volume":"73","author":"Wallis","year":"2018","journal-title":"Eur Urol"},{"issue":"12","key":"zoi210880r4","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.","volume":"25","author":"Loblaw","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi210880r5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"issue":"7","key":"zoi210880r6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"issue":"23","key":"zoi210880r7","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer.","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"zoi210880r8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003845","article-title":"A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.","volume":"95","author":"Sciarra","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"zoi210880r9","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease.","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"issue":"3","key":"zoi210880r10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"issue":"26","key":"zoi210880r11","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","article-title":"Androgen deprivation therapy and cardiovascular risk.","volume":"29","author":"Punnen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi210880r12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.urolonc.2019.02.010","article-title":"Androgen deprivation therapy and cardiovascular disease.","volume":"38","author":"Melloni","year":"2020","journal-title":"Urol Oncol"},{"issue":"1","key":"zoi210880r13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaccao.2020.01.004","article-title":"Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE Trial study design.","volume":"2","author":"Melloni","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"23","key":"zoi210880r14","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi210880r15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.juro.2018.09.029","article-title":"Minority recruitment trends in phase III prostate cancer clinical trials (2003 to 2014): progress and critical areas for improvement.","volume":"201","author":"Balakrishnan","year":"2019","journal-title":"J Urol"},{"issue":"8","key":"zoi210880r17","first-page":"464","article-title":"Real-world evidence: promise and peril for medical product evaluation.","volume":"43","author":"Dhruva","year":"2018","journal-title":"P T"},{"issue":"10","key":"zoi210880r18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12869","article-title":"Feasibility of using real-world data to replicate clinical trial evidence.","volume":"2","author":"Bartlett","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi210880r19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00392-016-1025-6","article-title":"Electronic health records to facilitate clinical research.","volume":"106","author":"Cowie","year":"2017","journal-title":"Clin Res Cardiol"},{"issue":"7","key":"zoi210880r20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/jech.2004.029496","article-title":"Estimating causal effects from epidemiological data.","volume":"60","author":"Hern\u00e1n","year":"2006","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"zoi210880r21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1161\/CIRCOUTCOMES.114.001177","article-title":"Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review.","volume":"8","author":"Melloni","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"zoi210880r22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2017.3919","article-title":"Use of health care databases to support supplemental indications of approved medications.","volume":"178","author":"Fralick","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi210880r23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/SLA.0000000000000256","article-title":"Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures.","volume":"259","author":"Lonjon","year":"2014","journal-title":"Ann Surg"},{"issue":"3","key":"zoi210880r24","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jclinepi.2014.10.003","article-title":"A reanalysis of cluster randomized trials showed interrupted time-series studies were valuable in health system evaluation.","volume":"68","author":"Fretheim","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"zoi210880r25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jclinepi.2006.10.012","article-title":"A simulation using data from a primary care practice database closely replicated the women\u2019s health initiative trial.","volume":"60","author":"Tannen","year":"2007","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"zoi210880r26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/pds.v17:7","article-title":"Replicated studies of two randomized trials of angiotensin-converting enzyme inhibitors: further empiric validation of the \u2018prior event rate ratio\u2019 to adjust for unmeasured confounding by indication.","volume":"17","author":"Tannen","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"zoi210880r27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi210880r28","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","article-title":"Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.","volume":"12","author":"Berger","year":"2009","journal-title":"Value Health"},{"issue":"10","key":"zoi210880r29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The Reporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) statement.","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"issue":"7","key":"zoi210880r31","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system.","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"9","key":"zoi210880r32","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"2","key":"zoi210880r33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.v10.2","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"25","key":"zoi210880r34","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"3","key":"zoi210880r35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/pst.v11.3","article-title":"Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study.","volume":"11","author":"Gayat","year":"2012","journal-title":"Pharm Stat"},{"issue":"3","key":"zoi210880r36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards test and diagnostics base don weighted residuals.","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"446","key":"zoi210880r37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"zoi210880r38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12265-019-09942-w","article-title":"Effect of androgen deprivation therapy on metabolic complications and cardiovascular risk.","volume":"13","author":"Melloni","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"issue":"1","key":"zoi210880r39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"issue":"3","key":"zoi210880r40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"Prasad","year":"2013","journal-title":"JAMA"},{"key":"zoi210880r16","unstructured":"US Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and Food and Drug Administration staff. Published August 20, 2017. Accessed October 1, 2020. https:\/\/www.fda.gov\/downloads\/medicaldevices\/deviceregulationandguidance\/guidancedocuments\/ucm513027.pdf"},{"key":"zoi210880r30","unstructured":"Wallach? JD, Deng? Y, McCoy? R, . Predicting the characteristics and results of the PRONOUNCE trial: study protocol. Published August 2020. Accessed September 21, 2021. https:\/\/medicine.yale.edu\/core\/current_projects\/CERSI\/PRONOUNCE%20Protocol%2020-09-30_396749_153_36283_v2.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2785385\/wallach_2021_oi_210880_1634243147.84168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T15:46:27Z","timestamp":1634917587000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2785385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.30587","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}